Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

GENMAB

GMAB.CODK0010272202NASDAQ CopenhagenDKDKK
Stock price
GENMAB
Loading chart...

Coverage

Latest articles

Genmab's experimental cancer drug shows encouraging results in endometrial cancer trial
8 Jun 2025, 20:28GMAB.CONASDAQ Copenhagen

Filings

Recent filings

FilingDate
Genmab Announces Financial Results for the First Half 2012 and Improves 2012 Financial Guidance15 Aug 2012
Arzerra Second Quarter 2012 Net Sales Figures25 Jul 2012
Genmab Enters Broad Collaboration with Janssen Biotech, Inc. for DuoBody Platform12 Jul 2012
Timing of Genmab’s Daratumumab Presentations at EHA Congress14 Jun 2012
Genmab Enters DuoBody Technology Collaboration4 Jun 2012
Genmab Outlicenses HuMax-IL830 May 2012
Genmab to Present at Jefferies Conference in June29 May 2012
Milestone Triggered in Connection with Filing of New Drug Application in Japan for Arzerra
Search

Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.

  • Previous
  • 1
  • 2
  • 3
  • Next
24 May 2012
Daratumumab Clinical Data to Be Presented at ASCO and EHA17 May 2012
Genmab Announces Financial Results for the First Quarter 201215 May 2012
Articles of Association of Genmab A/S8 May 2012
New Drug Application for Arzerra Submitted in Japan27 Apr 2012
  • Previous
  • 1
  • More pages
  • 92
  • 93
  • 94
  • More pages
  • 156
  • Next
Company
GENMAB
GMAB.CONASDAQ Copenhagen
Website: Unavailable
Coverage
13
Filings
1,863